Durable metabolic improvements 2 years after duodenal mucosal resurfacing (DMR) in patients with type 2 diabetes (REVITA-1 Study)
Annieke C G van Baar, Jacques Devière, David Hopkins, Laurent Crenier, Frits Holleman, Manoel P Galvão Neto, Pablo Becerra, Paulina Vignolo, Leonardo Rodriguez Grunert, Geltrude Mingrone, Guido Costamagna, Max Nieuwdorp, Caterina Guidone, Rehan J Haidry, Bu Hayee, Cormac Magee, Juan Carlos Lopez-Talavera, Kelly White, Vijeta Bhambhani, Emily Cozzi, Harith Rajagopalan, Jacques J G H M Bergman, Annieke C G van Baar, Jacques Devière, David Hopkins, Laurent Crenier, Frits Holleman, Manoel P Galvão Neto, Pablo Becerra, Paulina Vignolo, Leonardo Rodriguez Grunert, Geltrude Mingrone, Guido Costamagna, Max Nieuwdorp, Caterina Guidone, Rehan J Haidry, Bu Hayee, Cormac Magee, Juan Carlos Lopez-Talavera, Kelly White, Vijeta Bhambhani, Emily Cozzi, Harith Rajagopalan, Jacques J G H M Bergman
Abstract
Aims: Duodenal mucosal resurfacing (DMR) is an endoscopic procedure developed to improve metabolic parameters and restore insulin sensitivity in patients with diabetes. Here we report long-term DMR safety and efficacy from the REVITA-1 study.
Materials and methods: REVITA-1 was a prospective, single-arm, open-label, multicenter study of DMR feasibility, safety, and efficacy in patients with type 2 diabetes (hemoglobin A1c [HbA1c] of 7.5-10.0% (58-86 mmol/mol)) on oral medication. Safety and glycemic (HbA1c), hepatic (alanine aminotransferase [ALT]), and cardiovascular (HDL, triglyceride [TG]/HDL ratio) efficacy parameters were assessed (P values presented for LS mean change).
Results: Mean ± SD HbA1c levels reduced from 8.5 ± 0.7% (69.1 ± 7.1 mmol/mol) at baseline (N = 34) to 7.5 ± 0.8% (58.9 ± 8.8 mmol/mol) at 6 months (P < 0.001); and this reduction was sustained through 24 months post-DMR (7.5 ± 1.1% [59.0 ± 12.3 mmol/mol], P < 0.001) while in greater than 50% of patients, glucose-lowering therapy was reduced or unchanged. ALT decreased from 38.1 ± 21.1 U/L at baseline to 32.5 ± 22.1 U/L at 24 months (P = 0.048). HDL and TG/HDL improved during 24-months of follow-up. No device- or procedure-related serious adverse events, unanticipated device effects, or hypoglycemic events were noted between 12 and 24 months post-DMR.
Conclusions: DMR is associated with durable improvements in insulin sensitivity and multiple downstream metabolic parameters through 24 months post-treatment in type 2 diabetes. Clinical trial reg. no. NCT02413567, clinicaltrials.gov.
Keywords: Duodenal mucosal resurfacing; Duodenum; Endoscopic ablation; Type 2 diabetes mellitus.
Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.
Source: PubMed